Canton Hathaway’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$141K Hold
1,000
– – 0.03% 146
2026
Q2
$123K Hold
1,000
– – 0.02% 158
2026
Q1
$105K Hold
1,000
– – 0.02% 155
2025
Q4
$87.3K Buy
+1,000
New +$81.8K 0.02% 169

Other funds holding PTGX

Canton Hathaway's PTGX Position: Q3 2026 in Review

Canton Hathaway held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 1,000 shares worth $141K. The position accounts for 0.03% of the portfolio, ranked #146.

Canton Hathaway first reported a position in PTGX in Q4 2025 and has held it in 4 quarters since. 376 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Canton Hathaway held 1,000 shares of Protagonist Therapeutics worth $141K as of Q3 2026.
  • Canton Hathaway left its Protagonist Therapeutics share count unchanged in Q3 2026.
  • Protagonist Therapeutics made up 0.03% of Canton Hathaway's portfolio in Q3 2026, its #146 holding.
  • Canton Hathaway first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 376 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Canton Hathaway's 13F filing for Q3 2026, filed 23 Oct 2026.